Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Bay X 1005

Known as: Bay X1005, BAYX-1005, Bay-X1005 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
  • A. Sampson
  • Current opinion in investigational drugs
  • 2009
  • Corpus ID: 33308030
Leukotrienes are lipid inflammatory mediators that are implicated in asthma, COPD, arthritis, cardiovascular disease and cancer… 
2007
2007
Methods: Investigators conducted a prospective, randomized, placebo-controlled, crossover trial of the leukotriene antagonist (DG… 
Highly Cited
2005
Highly Cited
2005
ContextMyocardial infarction (MI) is the leading cause of death in the world. Variants in the 5-lipoxygenase–activating protein… 
Highly Cited
2005
Highly Cited
2005
CONTEXT Myocardial infarction (MI) is the leading cause of death in the world. Variants in the 5-lipoxygenase-activating protein… 
Highly Cited
2005
Highly Cited
2005
BACKGROUND MMP-13 is one of the most important metalloproteases (MMP) involved in osteoarthritis. Licofelone, a novel dual… 
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2002
Highly Cited
2002
OBJECTIVE To compare the effect of licofelone, NS-398 (an inhibitor of cyclooxygenase 2 [COX-2]), and BayX-1005 (an inhibitor of… 
Review
1997
Review
1997
This article reviews the literature on the effects of leukotrienes in asthma. In particular, the ability of recently developed…